|
Market Closed -
Nasdaq
00:00:00 22/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.5613 USD | +7.94% |
|
-0.44% | -64.47% |
| 09-21 | Outlook Therapeutics, Inc.(NasdaqCM:OTLK) added to S&P Global BMI Index | CI |
| 08-28 | Outlook Therapeutics, Inc. Announces CFO Changes, Effective September 1, 2026 | CI |
Company Valuation: Outlook Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: September | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 380.5 | 275.9 | 57.51 | 126.3 | 47.08 | 126.6 | - | - |
| Change | - | -27.49% | -79.15% | 119.63% | -62.73% | 168.86% | - | - |
| Enterprise Value (EV) | 380.5 | 275.9 | 57.51 | 126.3 | 47.08 | 126.6 | 126.6 | 126.6 |
| Change | - | -27.49% | -79.15% | 119.63% | -62.73% | 168.86% | 0% | 0% |
| P/E | -6.2x | -3.94x | -0.92x | -1.32x | -0.59x | -0.9x | -2.4x | 5.78x |
| PBR | 71.9x | 29.6x | - | - | - | - | - | - |
| PEG | - | 0.3x | 0x | 0.1x | 0x | 0x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | 33.3x | 185x | 2.87x | 0.74x |
| EV / Revenue | - | - | - | - | 0x | 185x | 2.87x | 0.74x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -2.38x | -3.71x | 1.58x |
| EV / FCF | - | -0x | -0x | - | - | -3.25x | -11.5x | 0.94x |
| FCF Yield | - | -20.5% | -74.7% | - | - | -30.8% | -8.69% | 107% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7 | -6.2 | -4.8 | -4.06 | -1.79 | -0.58 | -0.2167 | 0.09 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | 1.413 | 0.6827 | 44.07 | 170.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -51.73 | -63.07 | -53.13 | -71.7 | -67.06 | -53.11 | -34.16 | 80.01 |
| Net income 1 | -53.16 | -66.05 | -58.98 | -75.37 | -62.42 | -65.1 | -44.43 | 20.8 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 43.4000 | 24.4000 | 4.4200 | 5.3400 | 1.0600 | 0.5200 | 0.5200 | 0.5200 |
| Nbr of stocks (in thousands) | 8,767 | 11,307 | 13,012 | 23,656 | 44,420 | 243,448 | - | - |
| Announcement Date | 22/12/21 | 29/12/22 | 22/12/23 | 27/12/24 | 19/12/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.9x | - | - | - | 127M | |
| 19.21x | 6.83x | 13.69x | 1.55% | 66.34B | |
| 36.32x | 6.47x | 19.31x | 0.89% | 52.92B | |
| 29.51x | 8.11x | 25.65x | 0.05% | 54.82B | |
| 34.13x | 3.33x | 14.37x | -.--% | 44.09B | |
| 50.62x | 5.85x | 32.15x | -.--% | 43.72B | |
| -20.41x | 209.35x | -21.69x | -.--% | 42.13B | |
| 29.48x | 8.35x | 21.6x | 0.36% | 33.96B | |
| 30.25x | 6.41x | 16.63x | -.--% | 26.17B | |
| 31.94x | 5.89x | 19.81x | -.--% | 23.37B | |
| Average | 24.01x | 28.95x | 15.73x | 0.32% | 38.76B | |
| Weighted average by Cap. | 26.34x | 28.52x | 15.73x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- OTLK Stock
- Valuation Outlook Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
